Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 4/20 | 0.50 |
| ▸ | HRH1 | P35367 | 4/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20766517 | 0.89 | MMP2 (0.56) | HRH3SIGMAR1MAPTALDH1A1HRH2 | |
| SCHEMBL5519875 | 0.87 | HRH3 (0.62) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL7384498 | 0.87 | HRH3 (0.59) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL7983991 | 0.85 | HRH3 (0.66) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL12408526 | 0.85 | HRH3 (0.66) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL5526919 | 0.85 | HRH3 (0.66) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL7387284 | 0.85 | HRH3 (0.66) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL7986752 | 0.84 | ALDH1A1 (0.66) | HRH3MAPTALDH1A1HRH2HRH1 | |
| SCHEMBL1715325 | 0.83 | HRH3 (0.53) | HRH3MAPTALDH1A1HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL4382750 | 0.82 | HRH3 (0.51) | HRH3MAPTALDH1A1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-117466803-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-111132976-B | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200270239-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200270239-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2020-08-27 | — | — | US | disclosed |
| EP-3672960-A2 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | Acadia Pharmaceuticals Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3672954-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | Acadia Pharmaceuticals Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-111132976-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2020-05-08 | — | — | CN | disclosed |
| WO-2019040107-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040107-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040104-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040104-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270239-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | HRH3 2662/4885SIGMAR1 2137/4885MAPT 1125/4885 |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | HRH3 2662/4885SIGMAR1 2137/4885MAPT 1125/4885 |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | HRH3 2662/4885SIGMAR1 2137/4885MAPT 1125/4885 |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | HRH3 2662/4885SIGMAR1 2137/4885MAPT 1125/4885 |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, VHL, CYP11B2 | HRH3 3364/4885SIGMAR1 2526/4885MAPT 1266/4885 |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, VHL, CYP11B2 | HRH3 3364/4885SIGMAR1 2526/4885MAPT 1266/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | HRH3 2662/4885SIGMAR1 2137/4885MAPT 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.